Retatrutide: Understanding the GLP-1R/GIPR/GCGR Tri-Agonist in Research Settings

Retatrutide has a molecular weight of 4757.4 g/mol and the molecular formula C₂₁₉H₃₄₂N₄₄O₆₈. It is supplied as a white lyophilised powder, stored at −20°C, and is intended exclusively for in-vitro laboratory research. It is not approved for human use outside of controlled clinical trial settings and is not available as a licensed medicine in the UK.

Understanding retatrutide's research profile requires familiarity with the three receptor systems it targets:

• GLP-1R is expressed on pancreatic beta cells and plays a central role in glucose-stimulated insulin secretion. It has been extensively studied in the context of metabolic cell signalling.
• GIPR is co-expressed with GLP-1R in several tissue types and its role in energy homeostasis has been the subject of growing investigation, particularly following the clinical success of dual GLP-1R/GIPR agonists.
• GCGR mediates glucagon signalling and is involved in hepatic glucose output regulation. Its inclusion in a tri-agonist profile represents a distinct approach compared to existing dual-agonist compounds.

Laboratory investigations involving retatrutide have examined receptor binding kinetics, downstream signalling pathway activation in cell culture models, and comparative receptor occupancy studies. Researchers have used it to study the differential effects of simultaneous multi-receptor engagement versus sequential or single-receptor activation.

As with all research peptides, findings from cell-based assays represent mechanistic investigation only and do not constitute clinical evidence.

Retatrutide should be stored at −20°C in lyophilised form. HPLC-verified purity of ≥98% is the minimum acceptable standard for reproducible research results. A lot-specific CoA should be obtained for every batch used in published research.